Modulation of IL-12/IL-23 signaling pathways by ustekinumab alleviates inflammation in Crohn’s disease patients

Česká verzia

Authors: J. Krejsek
Authors place of work: Ústav klinické imunologie a alergologie, LF UK a FN Hradec Králové
Published in the journal: Gastroent Hepatol 2018; 72(4): 334-339
Category:
doi: https://doi.org/10.14735/amg2018334

Summary

Crohn’s disease (CD) is a multifactorial illness, in which pathogenesis involving damage to the inflammatory response, mediated by abnormally polarized Th1 and Th17 subsets of T cell, is a prominent feature. CD treatment options employing biological therapies, predominantly based on antitumor necrosis factor α biologics, are limited compared with other immunological diseases. With the exception of vedolizumab among numerous other biologics tested so far, clinical efficacy has recently been approved only for ustekinumab, which targets subunit p40 shared by both IL-12 and IL-23 interleukins. Interleukin-12 is indispensable for the functional polarization of T cells into the Th1 subset. Interleukin-23 is essential for the full activation and survival of the Th17 subset of T cells. Immunomodulatory intervention employing targeting of IL-12/IL-23 signaling pathways via ustekinumab alleviates inflammatory reactions in patients with CD. In addition, ustekinumab treatment is not associated with an increased risk of immunity impairment or decreased protective and barrier function of gut mucosa, which are common side effects of other biologics, especially those targeting IL-17/IL-17R signaling pathways. The clinical efficacy of another treatment targeting the unique subunit of p19 of IL-23 in CD patients is now being tested in ongoing clinical trials.

Key words:

Crohn’s disease – inflammation – Th1/Th17 subsets – signaling pathway IL-12/IL-23 – biological therapy – ustekinumab

The authors declare they have no potential conflicts of interest concerning drugs, products, or services used in the study.

The Editorial Board declares that the manuscript met the ICMJE „uniform requirements“ for biomedical papers.

Submitted: 4. 6. 2018

Accepted: 4. 7. 2018

Zdroje

1. Buc M. Súčasné a perspektívne biologiká a malé molekuly v liečbe idiopatických zápalových chorôb čreva. Vnitř Lék 2018; 64 (3): 280–289.

2. Krejsek J, Andrýs C, Krčmová I. Imunologie člověka. Hradec Králové: Garamon 2016. [online]. Dostupné z: http: //www.imunologie-cloveka-krejsek.cz.

3. Pagliari D, Gambassi G, Piccirillo CA et al. The intricate link among gut “Immunological Niche,” microbiota, and xenobiotics in intestinal pathology. Mediators Inflamm 2017; 8390595. doi: 10.1155/2017/8390595.

4. Petkova DS, Viret C, Faure M. IRGM in autophagy and viral infections. Front immunol 2013; 3: 426. doi: 10.3389/fimmu.2012.00426.

5. Verstockt B, Smith KG, Lee JC. Genome-wide association studies in Crohn’s disease: Past, present and future. Clin Transl Immunology 2018; 7 (1): e1001. doi: 10.1002/cti2.1001.

6. Lei-Leston AC, Murphy AG, Maloy KJ. Epithelial cell inflammasomes in intestinal immunity and inflammation. Front Immunol 2017; 8: 1168. doi: 10.3389/fimmu.2017.01168.

7. de Bruyn M, Vermeire S. NOD2 and bacterial recognition as therapeutic targets for Crohn’s disease. Expert Opin Ther Targets 2017; 21 (12): 1123–1139. doi: 10.1080/14728222.2017.

8. Nishida A, Inoue R, Inatomi O et al. Gut microbiota in the pathogenesis of inflammatory bowel disease. Clin J Gastroenterol 2018; 11 (1): 1–10. doi: 10.1007/s12328-017-0813-5.

9. Lane ER, Zisman TL, Suskind DL. The microbiota in inflammatory bowel disease: current and therapeutic insights. J Inflamm Res 2017; 10: 63–73. doi: 10.2147/JIR.S116088.

10. Opazo MC, Ortega-Rocha EM, Coronado-Arrázola I et al. Intestinal microbiota influences non-intestinal related autoimmune diseases. Front Microbiol 2018; 9 (432). doi: 10. 3389/fmicb.2018.00432.

11. Taylor PR, Roy S, Leal SM et al. Activation of neutrophils by autocrine IL-17A-IL-17RC interactions during fungal infection is regulated by IL-6, IL-23, RORγt and dectin-2. Nat Immunol 2014; 15 (2): 143–151. doi: 10.1038/ni.2797.

12. Maxwell JR, Zhang Y, Brown WA et al. Differential roles for interleukin-23 and interleukin-17 in intestinal immunoregulation. Immunity 2015; 43 (4): 739–750.

13. Machado A, Torres T. Guselkumab for the treatment of psoriasis. BioDrugs 2018; 32 (2): 119–128. doi: 10.1007/s40259-018-0265-6.

14. Ramos GP, Faubion WA, Papadakis KA. Targeting specific immunologic pathways in Crohn’s disease. Gastroenterol Clin North Am 2017; 46 (3): 577–588. doi: 10.1016/j.gtc.2017. 05.009.

15. Segal AW. Making sense of the cause of Crohn’s – a new look at an old disease. Version 2. F1000Res 2016; 5: 2510. doi: 10.12688/ f1000research.9699.2.

16. Abraham C, Dulai PS, Vermeire S et al. Lessons learned from trials targeting cytokine pathways in patients with inflammatory bowel diseases. Gastroenterology 2017; 152 (2): 374–388. doi: 10.1053/j.gastro.2016.10. 018.

17. Hueber W, Sands BE, Lewitzky S et al. Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn’s disease: unexpected results of a randomised, double-blind placebo-controlled trial. Gut 2012; 61 (12): 1693–1700. doi: 10.1136/gutjnl-2011-301 668.

18. Lee JS, Tato CM, Joyce-Shaikh B et al. Interleukin-23-independent IL-17 production regulates intestinal epithelial permeability. Immunity 2015; 43 (4): 727–738. doi: 10.1016/j.immuni.2015.09.003.

19. MacDonald JK, Nguyen TM, Khanna R et al. Anti-IL-12/23p40 antibodies for induction of remission in Crohn’s disease. Cochrane Database Syst Rev 2016; 11: CD007572.

20. Deepak P, Sandborn WJ. Ustekinumab and anti-interleukin-23 agents in Crohn’s disease. Gastroenterol Clin North Am 2017; 46 (3): 603–626. doi: 10.1016/j.gtc.2017.05.013.

21. Kotze PG, Ma C, Almutairdi A et al. Clinical utility of ustekinumab in Crohn’s disease. J Inflamm Res 2018; 11: 35–47. doi: 10.2147/JIR.S157358.

22. Furfaro F, Gilardi D, Allocca M et al. IL-23 blockade for Crohn’s disease: next generation of anti-cytokine therapy. Expert Rev Clin Immunol 2017; 13 (5): 457–467. doi: 10.1080/ 1744666X.2017.1279055.

23. Feagan BG, Sandborn WJ, D’Haens G et al. Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn’s disease: a randomised, double-blind, placebo-controlled phase 2 study. Lancet 2017; 389 (10080): 1699–1709. doi: 10.1016/S0140-6736 (17) 30 570-6.

24. Catalan-Serra I, Brenna Ø. Immunotherapy in inflammatory bowel disease: novel and emerging treatments. Hum Vaccin Immunother 2018; 1–15. doi: 10.1080/21645515.2018.1461 297.

25. Aoki, M, Aoki H, Ramanathan R et al. Sphingosine-1-phosphate signaling in immune cells and inflammation: roles and therapeutic potential. Mediators Inflamm 2016; 8606878. doi: 10.1155/2016/8606878.

26. Catalan-Serra I, Brenna Ø. Immunotherapy in inflammatory bowel disease: Novel and emerging treatments. Hum Vaccin Immunother 2018. In press. doi: 10.1080/21645515.2018.1461297.